
Pieter van Baal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2352905/publications.pdf Version: 2024-02-01



ΔΙΕΤΕΟ ΜΑΝ ΒΛΛΙ

#	Article	IF	CITATIONS
1	The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. Pharmacoeconomics, 2022, 40, 233-239.	1.7	4
2	Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands. Value in Health, 2022, 25, 731-735.	0.1	12
3	Distributional consequences of including survivor costs in economic evaluations. Health Economics (United Kingdom), 2021, 30, 2606-2613.	0.8	3
4	The economics of improving global infectious disease surveillance. BMJ Global Health, 2021, 6, e006597.	2.0	11
5	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. Social Science and Medicine, 2021, 289, 114414.	1.8	3
6	Improving maternal and child health in Pakistan: a programme evaluation using a difference in difference analysis. BMJ Global Health, 2021, 6, e006453.	2.0	3
7	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. Value in Health, 2020, 23, 1027-1033.	0.1	10
8	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. European Journal of Health Economics, 2020, 21, 1329-1350.	1.4	3
9	Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0. Value in Health, 2020, 23, 1453-1461.	0.1	11
10	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Effectiveness and Resource Allocation, 2020, 18, 13.	0.6	11
11	Prospective impact of tobacco eradication and overweight and obesity eradication on future morbidity and health-adjusted life expectancy: simulation study. Journal of Epidemiology and Community Health, 2020, 74, 354-361.	2.0	7
12	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. European Journal of Health Economics, 2019, 20, 175-180.	1.4	73
13	A costâ€effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics (United Kingdom), 2019, 28, 87-100.	0.8	39
14	Future unrelated medical costs need to be considered in cost effectiveness analysis. European Journal of Health Economics, 2019, 20, 1-5.	1.4	25
15	Health care input constraints and cost effectiveness analysis decision rules. Social Science and Medicine, 2018, 200, 59-64.	1.8	26
16	Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. BMJ: British Medical Journal, 2017, 359, j5096.	2.4	14
17	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Costâ€Effectiveness Analysis. Health Economics (United Kingdom), 2016, 25, 237-248.	0.8	41
18	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. Health Economics (United Kingdom), 2016, 25, 1005-1019.	0.8	12

PIETER VAN BAAL

#	Article	IF	CITATIONS
19	Forecasting differences in life expectancy by education. Population Studies, 2016, 70, 201-216.	1.1	20
20	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics (United Kingdom), 2016, 25, 933-938.	0.8	23
21	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. European Journal of Public Health, 2015, 25, 791-795.	0.1	14
22	Trends in Dutch hospital spending by age and disease 1994–2010. Health Policy, 2015, 119, 316-323.	1.4	6
23	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al Pharmacoeconomics, 2013, 31, 369-373.	1.7	12
24	Important cost categories not included: transcatheter aortic valve implantation probably less cost-effective. Heart, 2012, 98, 1182.1-1182.	1.2	0
25	DYNAMO-HIA–A Dynamic Modeling Tool for Generic Health Impact Assessments. PLoS ONE, 2012, 7, e33317.	1.1	51
26	PAID 1.0 in Practice. Pharmacoeconomics, 2011, 29, 545-547.	1.7	1
27	Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. Population Health Metrics, 2011, 9, 17.	1.3	39
28	LONGâ€TERM EFFECTS OF ALCOHOL POLICIES: AN ECONOMIC PERSPECTIVE. Addiction, 2010, 105, 395-397.	1.7	1
29	The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. Preventive Medicine, 2008, 46, 127-132.	1.6	28
30	Realistic Spatial Backcloth is not that Important in Agent Based Simulation Research. , 2008, , 19-34.		13
31	Economics and public health: engaged to be happily married!. European Journal of Public Health, 2007, 17, 122-123.	0.1	15